GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial. The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) in combination with bortezomib plus dexamethasone (DVd) as a second line or later treatment for relapsed or refractory multiple myeloma.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...
Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...
Medpage Today on MSN10d
Year in Review: Multiple MyelomaOne of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...
The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The ...
Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...
GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback